Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardion Health Sciences, Inc.none · Entity 87936 | Chief Accounting Officer · Controller | August 30, 2017 | August 30, 2017 |
| Unicycive Therapeutics, Inc.UNCY · Entity 6568 | CFO | May 14, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardion Health Sciences, Inc.
Report date August 30, 2017 · Filed August 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,000 |
Reported balance
After 2017-08-30 transaction · row 1
1 source rowRow 1 · 2017-08-30 · Grant · Acquired 100,000 · Balance 105,000 F1: The Board of Directors authorized the grant on August 10, 2017. The stock certificate representing the shares was delivered to Reporting Person on August 30, 2017. F2: These shares are fully vested upon issuance. |
Filing footnotes · ownership attribution and instrument terms
F1: The Board of Directors authorized the grant on August 10, 2017. The stock certificate representing the shares was delivered to Reporting Person on August 30, 2017.
F2: These shares are fully vested upon issuance.
Unicycive Therapeutics, Inc.
Report date May 14, 2026 · Filed June 15, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 169,500 |
Reported balance
After 2026-05-14 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 169,500 · Balance 169,500 F1: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 20, 2026 20:30 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantRestricted Stock Unit · Derivative | 169,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-059559 · ownership.xml · derivative · entry 1 Townsend John · CIK 0001511906 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,500 Underlying: Common Stock · 169,500 shares Expires not disclosed F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed Jun 15, 2026 21:23 UTC Amendment | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantRestricted Stock Unit · Derivative | 169,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-068917 · ownership.xml · derivative · entry 1 Townsend John · CIK 0001511906 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,500 Underlying: Common Stock · 169,500 shares Expires not disclosed F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 23,542 shares vest upon grant and 4,708 shares vest over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:30 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantStock Options · Derivative | 10,000 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001213900-25-069302 · ownership.xml · derivative · entry 1 Townsend John · CIK 0001511906 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,557 Underlying: Common Stock · 10,000 shares Expires 2035-07-28 F1 · derivative.exercise_date: 2,500 of the stock options vest on July 28, 2026 and 1/36th of the remaining options vest at the end of each successive month thereafter. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:15 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantStock Options · Derivative | 40,256 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001213900-24-069038 · ownership.xml · derivative · entry 1 Townsend John · CIK 0001511906 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 915,565 Underlying: Common Stock · 40,256 shares Expires 2034-08-12 F1 · derivative.exercise_date: 10,064 of the stock options vest on August 12, 2025 and 1/36th of the remaining options vest at the end of each successive month thereafter. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 20:33 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantStock Options · Derivative | 228,119 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001213900-24-033833 · ownership.xml · derivative · entry 1 Townsend John · CIK 0001511906 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 875,309 Underlying: Common Stock · 228,119 shares Expires 2034-04-15 F1 · derivative.exercise_date: 57,030 of the stock options vest on the first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 20:46 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantStock Options · Derivative | 570,329 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001213900-23-072249 · ownership.xml · derivative · entry 1 Townsend John · CIK 0001511906 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 647,190 Underlying: Common Stock · 570,329 shares Expires 2033-08-28 F1 · derivative.exercise_date: 142,582 of the stock options vest on March 6, 2024 and 1/36th of the remaining options vest at the end of each successive month thereafter. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 13:00 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001213900-22-074723 · ownership.xml · derivative · entry 1 Townsend John · CIK 0001511906 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,861 Underlying: Common Stock · 35,000 shares Expires 2032-11-21 F1 · derivative.exercise_date: 8,750 of the stock options vest on first anniversary of the date of grant and 1/36th of the remaining options vest at the end of each successive month thereafter. Read SEC document |
| July 15, 2021 Filed Jul 26, 2021 20:15 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantStock Options · Derivative | 18,605 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-21-038634 · ownership.xml · derivative · entry 1 Townsend John · CIK 0001511906 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,861 Underlying: Common Stock · 18,605 shares Expires 2031-07-15 F1 · derivative.exercise_date: The stock options vest equally over a period of three years from the date of grant. Read SEC document |
| August 30, 2017 Filed Aug 30, 2017 23:33 UTC | Guardion Health Sciences, Inc. none · Entity 87936 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001511906-17-000003 · primary_doc.xml · nonDerivative · entry 1 Townsend John · CIK 0001511906 · Chief Accounting Officer · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 F1 · date: The Board of Directors authorized the grant on August 10, 2017. The stock certificate representing the shares was delivered to Reporting Person on August 30, 2017. F2 · shares: These shares are fully vested upon issuance. Read SEC document |
| December 31, 2016 Filed Jan 3, 2017 21:36 UTC | Guardion Health Sciences, Inc. none · Entity 87936 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001135337-17-000005 · primary_doc.xml · nonDerivative · entry 1 Townsend John · CIK 0001511906 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · kind: Grant of restricted stock for services vesting 50% on June 30, 2017 and 50% on December 31, 2017. Read SEC document |
| December 31, 2016 Filed Feb 14, 2017 20:45 UTC Amendment | Guardion Health Sciences, Inc. none · Entity 87936 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001511906-17-000002 · primary_doc.xml · nonDerivative · entry 1 Townsend John · CIK 0001511906 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · kind: The Board of Directors removed the vesting requirement such that the shares vest immediately upon issuance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.